A detailed history of Pathstone Holdings, LLC transactions in Argenx Se stock. As of the latest transaction made, Pathstone Holdings, LLC holds 2,326 shares of ARGX stock, worth $1.41 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
2,326
Previous 1,801 29.15%
Holding current value
$1.41 Million
Previous $774,000 62.92%
% of portfolio
0.01%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$434.22 - $551.9 $227,965 - $289,747
525 Added 29.15%
2,326 $1.26 Million
Q2 2024

Aug 14, 2024

BUY
$356.01 - $451.55 $66,573 - $84,439
187 Added 11.59%
1,801 $774,000
Q1 2024

May 13, 2024

BUY
$356.95 - $413.29 $144,564 - $167,382
405 Added 33.5%
1,614 $635,000
Q4 2023

Feb 14, 2024

BUY
$338.91 - $506.01 $409,742 - $611,766
1,209 New
1,209 $459,000

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $33.6B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Pathstone Holdings, LLC Portfolio

Follow Pathstone Holdings, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pathstone Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pathstone Holdings, LLC with notifications on news.